Lightnews — Scholar-powered news

Susan G. Komen @susangkomen.bsky.social · 3d

Today is National Donor Advised Fund Day! Consider using our quick and easy tool to make an immediate impact. Now more than ever, patients need your help.

Ending breast cancer needs all of us. Komen.org/DAF #DAFDay

Susan G. Komen @susangkomen.bsky.social · 6d

For someone with breast cancer, genomic testing can be a personalized guide that helps themchoose a treatment path with the greatest benefit while possibly avoiding unnecessary detours.

Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/

1

Susan G. Komen @susangkomen.bsky.social · 11d

4 years ago, we released a first-of-its-kind report highlighting the breast cancer disparities bet. Black & white women. Today, we’re sharing an update: in 9 major U.S. metro areas where outcomes were the worst, more Black lives are being saved from breast cancer.

Read more: https://bit.ly/4ojeKsz

1

Susan G. Komen @susangkomen.bsky.social · 12d

October is National Breast Cancer Awareness Month and it's time to take action. From advocating for cancer research funding to supporting equitable care for all, your voice matters!

Visit komen.org to join the fight. Because ending breast cancer needs all of us.

2 2

Susan G. Komen @susangkomen.bsky.social · 16d

In case you missed it, check out the latest Breast Cancer Breakthroughs focused on how ctDNA is poised to revolutionize breast cancer care and read our blog to learn what it means for patients.

Watch the event & read the blog here: https://bit.ly/48C56MO

Susan G. Komen @susangkomen.bsky.social · 16d

Imlunestrant was just approved by the FDA to treat ER-positive, HER2-negative ESR1-mutated metastatic breast cancer. The approval was based on results from the phase 3 EMBER-3 clinical trial.

Read more on our What's New Page: https://bit.ly/3IW3ToM

Susan G. Komen @susangkomen.bsky.social · 17d

Breast cancer is rising in women under 50, but thanks to lifesaving clinical trials, there’s hope on the horizon.

In our next Spotlight on Clinical Trials, we explore four current clinical trials that focus specifically on the needs of young women. https://bit.ly/42LaOrS

Susan G. Komen @susangkomen.bsky.social · 19d

NEW Breast Cancer Breakthroughs Sept. 25! Learn about how simple blood tests are being used to improve breast cancer care.

Info here: https://bit.ly/3X1yPW0

Susan G. Komen @susangkomen.bsky.social · 23d

Discover how complementary therapies can support and empower breast cancer patients through treatment and recovery in our next Spotlight on Clinical Trials blog, where we explore three clinical trials testing their safety and effectiveness.

Learn more: https://bit.ly/3KacV26

Susan G. Komen @susangkomen.bsky.social · 24d

Komen is joining #RallyMedRes to call on Congress to protect lifesaving research! Research funded by the NIH is at the cornerstone of new advances for #breastcancer care.

Take action and tell Congress to protect lifesaving research! #FundNIH #KomenAdvocacy

2

Susan G. Komen @susangkomen.bsky.social · 25d

Nueva Vida is 1 of the 8 orgs in the ShareForCures alliance, and they are dedicated to supporting Latinos whose lives have been affected by cancer. Breast cancer affects people from all backgrounds, yet not every community is appropriately represented in research.

Learn more: https://bit.ly/3K8umQA

Susan G. Komen @susangkomen.bsky.social · 27d

Breast cancer is the leading cause of cancer death among Hispanic women in the U.S. We want to change that.

This Hispanic Heritage Month, we encourage the Hispanic & Latino communities to take charge of their breast health, get screened & learn their family health histories. https://bit.ly/44Oxsy1

Susan G. Komen @susangkomen.bsky.social · Sep 12

The stage of breast cancer when it is diagnosed is an important factor when determining prognosis.

Learn about what each of these stages means: https://bit.ly/46iiNhb

Susan G. Komen @susangkomen.bsky.social · Sep 11

We will never forget those we lost on Sept. 11, 2001.

1

Susan G. Komen @susangkomen.bsky.social · Sep 10

Learn more about HER2+ MBC and the latest breakthroughs in research, clinical trials and treatment strategies at our upcoming MBC Impact Series.

🗓️ September 17th at 1pm CT / 2pm ET

Register today: https://bit.ly/4m6PzaX

Thank you to our partner AstraZeneca for supporting the MBC Impact Series.

Susan G. Komen @susangkomen.bsky.social · Sep 10

Funding for #breastcancer early detection & research programs is moving forward in Congress. As Congress continues negotiations for the federal budget, we urge lawmakers to protect & invest in these lifelines. Read our statement: https://bit.ly/4m67Bdz

Susan G. Komen @susangkomen.bsky.social · Jun 27

Susan G. Komen applauds today’s #SCOTUS decision to safeguard no-cost preventive care for more than 150 million Americans including #breastcancer patients, #survivors and those who are looking after their #breasthealth. Read more here: www.komen.org/news/susan-g...

2 1 2

Susan G. Komen @susangkomen.bsky.social · Jun 26

Breast surgery is often a part of breast cancer treatment, but recovery can bring unexpected challenges. Get answers and tips in our Know More blog covering 4 surprising challenges and how to manage them.

Read more: bit.ly/46eyc3y

Susan G. Komen @susangkomen.bsky.social · Jun 25

A Komen-supported study from UPMC shows how the “Hope for OTHERS” rapid autopsy program is reshaping metastatic breast cancer research through post-mortem tissue donation unlocking new treatment insights. bit.ly/44iUcb0

Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer - Breast Cancer Research

Breast cancer affects 1/8 of women throughout their lifetimes, with over 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in...

bit.ly

Susan G. Komen @susangkomen.bsky.social · Jun 23

In addition to this research investment, we also fund direct patient support through our Patient Care Center as well as breast cancer education, patient navigation, and public policy advocacy.

Learn more about the grants and their recipients: www.komen.org/blog/komen-b... (3/3)

Komen Invests in the Future of Breast Cancer Research

Susan G. Komen invests in the future of breast cancer research by announcing its latest slate of breast cancer research grants. Learn more.

www.komen.org

Susan G. Komen @susangkomen.bsky.social · Jun 23

“Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer,"" said Paula Schneider, President and CEO of Komen. (2/3)

1

Susan G. Komen @susangkomen.bsky.social · Jun 23

We are proud to announce our 2025 breast cancer research grants supporting cutting-edge projects that prioritize the most pressing challenges facing patients, including metastatic breast cancer, health inequities and the need for more precise, personalized treatment strategies. 🧵(1/3)

1

Susan G. Komen @susangkomen.bsky.social · Jun 3

@fatimacardoso.bsky.social shared results from the phase 3 OASIS-4 trial: Elinzanetant significantly reduced hot flash frequency and severity in women on hormone therapy for HR+ breast cancer. Results seen as early as week 1 and sustained through 52 weeks. #ASCO25

1

Susan G. Komen @susangkomen.bsky.social · Jun 3

Paola Zagami presented data supporting that in young women with HR+ breast cancer and BRCA mutations, adding ovarian suppression (OFS) to endocrine therapy improved disease-free and overall survival compared to tamoxifen alone. Supports OFS as key in adjuvant care for this group #ASCO25

Susan G. Komen @susangkomen.bsky.social · Jun 3

Jai Min Ryu shared 10-year ASTRRA trial results at #ASCO25: Adding 2 years of ovarian suppression to tamoxifen improved 10-year disease-free survival in premenopausal HR+ breast cancer. Greatest benefits observed in women 40–45 with high-risk tumors.

1